211 related articles for article (PubMed ID: 29528412)
1. High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.
Charpentier C; Peytavin G; Lê MP; Joly V; Cabras O; Perrier M; Le Gac S; Phung B; Yazdanpanah Y; Descamps D; Landman R
J Antimicrob Chemother; 2018 Jun; 73(6):1665-1671. PubMed ID: 29528412
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
Briand C; Dollfus C; Faye A; Kantor E; Avettand-Fenoel V; Caseris M; Descamps D; Schneider V; Tabone MD; Vaudre G; Veber F; Blanche S; Frange P
J Antimicrob Chemother; 2017 Mar; 72(3):837-843. PubMed ID: 27999017
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.
Gubavu C; Prazuck T; Niang M; Buret J; Mille C; Guinard J; Avettand-Fènoël V; Hocqueloux L
J Antimicrob Chemother; 2016 Apr; 71(4):1046-50. PubMed ID: 26712907
[TBL] [Abstract][Full Text] [Related]
4. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
Perrier M; Charpentier C; Peytavin G; Lê M; Blondel L; Visseaux B; Joly V; Pinto A; Matheron S; Yazdanpanah Y; Descamps D; Landman R
J Antimicrob Chemother; 2017 Jun; 72(6):1745-1751. PubMed ID: 28186251
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
Joly V; Burdet C; Landman R; Vigan M; Charpentier C; Katlama C; Cabié A; Benalycherif A; Peytavin G; Yeni P; Mentre F; Argoud AL; Amri I; Descamps D; Yazdanpanah Y;
J Antimicrob Chemother; 2019 Mar; 74(3):739-745. PubMed ID: 30476165
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
Cahn P; Rolón MJ; Figueroa MI; Gun A; Patterson P; Sued O
J Int AIDS Soc; 2017 May; 20(1):21678. PubMed ID: 28537061
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
[TBL] [Abstract][Full Text] [Related]
11. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Delory T; Papot E; Rioux C; Charpentier C; Auge-Courtoi C; Michard F; Peytavin G; Descamps D; Matheron S; Yazdanpanah Y
J Med Virol; 2016 Jul; 88(7):1204-10. PubMed ID: 26636432
[TBL] [Abstract][Full Text] [Related]
12. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Benatti S; Valenti D; Callegaro A; Ripamonti D; Mussini C
BMC Infect Dis; 2017 Mar; 17(1):215. PubMed ID: 28302065
[TBL] [Abstract][Full Text] [Related]
14. Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.
Gonzalez-Serna A; Glas AC; Brumme CJ; Poon AF; Nohpal De La Rosa A; Mudrikova T; Dias Lima V; Wensing AM; Harrigan R
J Antimicrob Chemother; 2017 Feb; 72(2):496-503. PubMed ID: 27999069
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
Frange P; Blanche S; Veber F; Avettand-Fenoel V
HIV Med; 2021 Nov; 22(10):958-964. PubMed ID: 34369051
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
Blanco JL; Rojas J; Paredes R; Negredo E; Mallolas J; Casadella M; Clotet B; Gatell JM; de Lazzari E; Martinez E;
J Antimicrob Chemother; 2018 Jul; 73(7):1965-1971. PubMed ID: 29608685
[TBL] [Abstract][Full Text] [Related]
18. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.
Wijting I; Rokx C; Boucher C; van Kampen J; Pas S; de Vries-Sluijs T; Schurink C; Bax H; Derksen M; Andrinopoulou ER; van der Ende M; van Gorp E; Nouwen J; Verbon A; Bierman W; Rijnders B
Lancet HIV; 2017 Dec; 4(12):e547-e554. PubMed ID: 29107562
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
